Loading stock data…
PALI
$1.99-0.01 (-0.50%)
Market ClosedLast close May 1
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Palisade Bio, Inc. in the Healthcare sector is trading at $1.99. The stock is currently 30% below its 52-week high of $2.86, remaining 23.6% above its 200-day moving average. Technical signals show neutral RSI of 50 and bearish MACD signal, explaining why PALI maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.99
Potential Upside
5%
Whystock Fair Value$2.09
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$392.23M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.47
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-12.97%
Volume
Today's trading volume
2.69M
Recent News
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile
We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Palisade Bio, Inc. is among the best biotech stocks to buy under $10. TheFly reported on April 8 that Wolfe Research initiated coverage of PALI with an Outperform rating and a $7 price target. The firm expects limited near-term activity […]
TSX Penny Stocks To Watch In March 2026
As Canada navigates a complex economic landscape marked by fluctuating oil prices and inflationary pressures, investors are keenly watching how these factors might impact market dynamics. Amidst this backdrop, penny stocks—though often associated with earlier trading days—remain an intriguing investment category for those seeking potential value in smaller or newer companies. By focusing on robust financials and growth potential, investors can uncover opportunities within the realm of penny...
Update: Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's Disease
(Updates with the company's latest stock move in the headline and the first paragraph.) Palisade
Palisade Bio Shares Phase 1b PALI-2108 Data Showing Safety, PK and Early Crohn’s Efficacy Signals
Palisade Bio (NASDAQ:PALI) said it generated encouraging safety, pharmacokinetic and early efficacy signals from an open-label Phase 1b study of PALI-2108 in fibrostenotic Crohn’s disease, a difficult-to-treat population where patients often progress from inflammation to structural fibrosis and may
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges
Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline.